Diagnósticos da América (DASA3) investor relations material

Executive summary

• Achieved consistent growth in revenue, margin, and volume for Q1 2026, reflecting structural initiatives, strategic repositioning, and operational simplification for greater efficiency and predictability.

• Margin expansion and improved efficiency driven by productivity gains, cost control, digitalization, and AI, with a focus on core business and user experience.

• Strengthened competitive positioning as a leading diagnostics platform in Latin America, maintaining a strong national platform and scalable infrastructure.

• Rede Américas joint venture progressing as planned, with synergy capture and asset management reinforcing medium- and long-term value creation.

• Free cash flow improved by R$101 million year-over-year, with robust cash generation expected for 2026 and ongoing leverage reduction.

Financial highlights

• Consolidated gross revenue rose 14% year-over-year (Current Scope), reaching R$2.4 billion; Diagnostics revenue up 15%, Hospitals and Oncology Northeast up 2%.

• Consolidated EBITDA increased 28% to R$573 million, with margin up 2.7 p.p. to 25.8%.

• Net income was R$9 million, reversing a R$111 million loss in 1Q25, driven by improved operations and lower financial expenses.

• Operating cash generation improved to R$21 million; free cash flow improved from a BRL 96 million outflow to a BRL 5 million inflow year-over-year.

• Financial leverage (net debt/EBITDA) decreased to 2.99x from 4.17x in 1Q25.

Outlook and guidance

• Expect robust free cash generation in 2026, with continued focus on core diagnostics, cost control, digitalization, and operational efficiency.

• Premium segment and home care expected to continue outpacing general market growth; second quarter anticipated to be weaker due to calendar effects, including the World Cup.